Gtrp: pharmacology/toxicology core laboratory project for RSA no. 2034
Ended Awarded Last action
- Contract number
- 75N92020F00002
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $625,344
Award facts
- Opportunity
-
- Gene Therapy Resource Program (GTRP) Pre-Solicitation · Posted Sep 19, 2017
- Contract value 100% obligated
- $625,343.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$480,276 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Definitize Change Order | $0 | |
| Original award | $1,105,620 |
About this award
This is a cost-plus-fixed-fee delivery order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $625,343.90 contract is for the PHARMACOLOGY/TOXICOLOGY CORE LABORATORY PROJECT under the Gene Therapy Resource Program (GTRP). Lovelace will provide a range of preclinical research services to support the development of gene therapy products, including animal studies, analytical testing, and disease model development. This contract does not have a set-aside designation. Lovelace has experience conducting nonclinical studies for federal agencies like NIH, FDA, and Department of Defense, and holds multiple federal contract and grant awards to support drug and medical countermeasure development across HHS components.
Quick answers
Who was awarded contract 75N92020F00002?
75N92020F00002 was awarded to Lovelace Biomedical Research Institute by National Heart Lung and Blood Institute (National Institutes of Health) on September 18, 2020.
How much is contract 75N92020F00002 worth?
The government has obligated $625,344 on 75N92020F00002.
Is contract 75N92020F00002 an order under another contract?
Yes. 75N92020F00002 is a delivery order under 75N92019D00017, an indefinite delivery contract.
Was contract 75N92020F00002 competed?
The extent of competition for 75N92020F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award